You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 22, 2024

Claims for Patent: 7,235,567

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 7,235,567

Title:	Crystalline polymorph of a bisulfate salt of a thrombin receptor antagonist
Abstract:	A crystalline polymorph of a bisulfate salt of a thrombin receptor antagonist compound, which exhibits a powder x-ray diffraction profile substantially the same as that shown in FIG. 1, or which exhibits a differential scanning calorimtery profile substantially the same as that shown in FIG. 3, and is represented by the formula for Compound 2: ##STR00001## and processes for preparing Compound 2 are disclosed. Pharmaceutical compositions comprising the polymorph of the bisulfate salt and at least one excipient or carrier, and methods of using the polymorph of Compound 2 to treat a variety of physiological disorders, such as thrombosis, are also disclosed.
Inventor(s):	Wu; Wenxue (Princeton Junction, NJ)
Assignee:	Schering Corporation (Kenilworth, NJ)
Application Number:	10/755,066
Patent Claims:	1. A crystalline polymorph Form 1 of Compound 2 of the formula: ##STR00009## that exhibits a powder x-ray diffraction pattern having characteristic peak locations of 11.2, 16.4, 19.2 and 21.0 degrees 2.theta.. 2. The crystalline polymorph of Compound 2 of claim 1 that exhibits a powder x-ray diffraction pattern having characteristic peak locations of 9.9, 11.2, 16.4, 19.2, 21.0, 22.1, 23.7 and 26.7 degrees 2.theta.. 3. The crystalline polymorph of Compound 2 of claim 1 that exhibits a powder x-ray diffraction pattern having characteristic peak locations of 9.9, 11.2, 12.6, 14.5, 16.4, 19.2, 21.0, 22.1, 23.7, 26.7, 28.2 and 30.8 degrees 2.theta.. 4. The crystalline polymorph of Compound 2 of claim 1 that exhibits a powder x-ray diffraction pattern substantially the same as the powder x-ray diffraction pattern shown in FIG 1. 5. A crystalline polymorph Form 1 of Compound 2 of the formula: ##STR00010## that exhibits a differential scanning calorimetry pattern substantially the same as the differential scanning calorimetry pattern shown in FIG. 3. 6. A pharmaceutical composition comprising the crystalline polymorph Form 1 of Compound 2 according to claim 1, and at least one excipient or carrier. 7. A purified form of the crystalline polymorph Form 1 of Compound 2 of claim 1.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.